Request Sample Inquiry
Car T-cell Therapy Market

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

180

Base Year:

2022

Date

Nov - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2336

Segments Covered
  • By Drug Type By Drug Type Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types
  • By Indication By Indication Lymphoma, Acute Lymphocytic Leukemia, Other Indications
  • By End User By End User Hospitals, Cancer Treatment Centers
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 2 Billion
Revenue 2030Revenue 2030: USD 5.9 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 14.6%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
CAR T-Cell Therapy Market Share

The global CAR T-Cell Therapy Market is valued at USD 2 Billion in 2022 and is projected to reach a value of USD 5.9 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 14.6% between 2023 and 2030.

Premium Insights

CAR T-Cell Therapy entails genetically changing a patient's T cells, a kind of immune cell, in order to target and attack cancer cells. The procedure begins with the extraction of T cells from the patient's blood. Following that, the T cells are genetically modified in the lab to express a receptor that binds to proteins identified on the patient's cancer cells. A chimeric antigen receptor (CAR-T) is a distinct type of receptor. Before being supplied to the patient, a large number of CAR T-Cell Therapy are created in the lab. CAR T-Cell Therapy is being studied for different cancers as well as for particular blood cancers. Chimeric antigen receptor T-cell therapy is another name for CAR T treatment. T cells are used in CAR T-Cell Therapy because they are responsible for the destruction of malignant and virus-infected cells. Cancer cells hide from the immune system. However, CAR-T treatment has improved T cells' ability to find and kill cancer cells.

CAR T-Cell Therapy Market Size, 2022 To 2030 (USD Billion)

AI (GPT) is here !!! Ask questions about CAR T-Cell Therapy Market
Loading....

  • Factors such as an increase in the number of cancer cases in adults and children, increased policy actions to stimulate cancer cell therapy research, and an increase in the number of clinical trials globally are the factors for CAR T-Cell Therapy market.
  • The Axicabtagene Ciloleucel segment is the leading segment for Drug type.
  • In 2022, North America dominated the global market and is projected to continue its dominance during the forecast period.
  • The Asia Pacific region will have the largest market growth rate between 2023 and 2030.

Top Market Trends

  1. T-cell-based approaches are now widely used in cancer immunotherapy due to their increased success rate. The majority of these are being carried out in East Asia, followed by the United States and, ultimately, Europe. This research demonstrates the growing usefulness of CAR treatments in cancer treatment. Furthermore, the majority of the important firms are investing in CD19 CART-T treatments in order to strengthen their market position in the coming years.
  2. The burgeoning gene therapy arena, on the other hand, is a critical component in the success of CAR T-Cell Therapy. As a result of increased investment, the gene therapy market is expected to expand further. These supportive measures have helped to boost market growth and attract investment in the CAR T-Cell Therapy industry.
  3. Furthermore, some governments have strengthened their support for CAR T-Cell Therapy by enacting legislation, establishing favorable reimbursement guidelines, partnering with private enterprises, and conducting clinical research studies to raise awareness of CAR T-Cell Therapy. As a result, increased awareness of CAR T-Cell Therapy is propelling the CAR T-Cell Therapy market forward.
  4. The CAR T-Cell Therapy industry is growing as a result of increased patient assistance programs (PAPs), increased government cancer awareness initiatives, rising cancer prevalence globally, and substantial R&D spending from key businesses. Manufacturers have begun to invest in cell-based therapeutic development as demand develops.
  5. Cell and gene therapy research has expanded quickly, extending the market for vehicle T-cell therapy. Scientists continue to explore the potential of this groundbreaking science, exploring new concepts and methods for manipulating T cells for enhanced anti-cancer action. As a consequence of ongoing research and development, CAR T-Cell Therapy treatment may become even more successful against cancer and hematological diseases. Such research and development will propel the market.
  6. Through regulatory authorization and great clinical results, CAR T-Cell Therapy have earned credibility and market growth. Because of its immense potential, regulatory organizations all over the world have approved CAR T-Cell Therapy for particular illnesses. CAR T-Cell Therapy, such as CAR T-Cell Therapy, have demonstrated incredible success in clinical studies, showing their efficacy and paving the way for their widespread adoption. Thus growing CAR T-Cell Therapy market.

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

  • Real-Time Data Updates:
  • Competitor Benchmarking
  • Market Trends Heatmap
  • Custom Research Queries
  • Market Sentiment Analysis
  • Demographic and Geographic Insights

Get Access Now

Economic Insights

CAR T-Cell Therapy development necessitates considerable research, clinical trials, and regulatory approvals, all of which might be prohibitively expensive. High research and development expenditures may limit the number of companies willing and able to invest in this industry. CAR T-Cell Therapy is frequently associated with high initial expenses, which can reach hundreds of thousands of dollars per treatment. The high cost of healthcare can put a burden on healthcare finances and limit patient access.CAR T-Cell Therapy require tailored manufacturing techniques for each patient, increasing the complexity and possible expense of manufacturing. Growing the business can be a logistical and financial hardship.

Market Segmentation

The Global CAR T-Cell Therapy Market is categorized into the segments as mentioned below:

The global CAR T-Cell Therapy market can be categorized into Drug Type, Indication, End User, Region. The CAR T-Cell Therapy market can be categorized into Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Other Drug Types based on Drug Type. The CAR T-Cell Therapy market can be categorized into Lymphoma, Acute Lymphocytic Leukemia, Other Indications based on Indication. The CAR T-Cell Therapy market can be categorized into Hospitals, Cancer Treatment Centers based on End User. The CAR T-Cell Therapy market can be categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa based on Region.

Below tree is interactive. You can click the nodes to get more information.

Based on Product Type

Axicabtagene Ciloleucel to Lead Maximum Market Share Due to the Use Of Adoption Of (Yescarta) Axicabtagene Ciloleucel Medicine

In 2022, due to the rising usage of the drug (Yescarta) Axicabtagene Ciloleucel for the treatment of relapsed or refractory follicular lymphoma and relapsed or refractory large B-cell lymphoma, the Axicabtagene Ciloleucel segment is the dominant segment for the worldwide market for CAR T-Cell Therapy. Yescarta is a drug with the active component Axicabtagene Ciloleucel. Yescarta's use in the treatment of diffuse large B-cell lymphoma and follicular lymphoma is likely to boost segment growth during the forecast period. Yescarta (Axicabtagene Ciloleucel) therapy has been shown to be more effective than other treatments. The medicine has high efficacy in treating diffuse large B-cell lymphoma (DLBCL), (HGBL), and (PMBCL) that had not responded to previous regimens. As a result, dominated the market for CAR T-Cell Therapy.

Based on Application

Hospital Segment Expects Dominion Owing to the Growing Increased Use of CAR T-Cell Therapy in Cancer Treatment

In 2022, the Hospitals segment will dominate the CAR T-Cell Therapy market. Chimeric antigen receptor T-cell therapy is a highly specialized treatment that necessitates close collaboration among many healthcare specialists, including hematologists, oncologists, and immunologists. This type of teamwork works best in a hospital context, where patients can receive comprehensive and integrated care from a multidisciplinary team. Furthermore, in certain cases, patients may need to be hospitalized for 7 to 10 days in order for healthcare practitioners to closely monitor their treatment response and appropriately address any potential adverse effects that may emerge. According to the Leukemia & Lymphoma Society, the total number of people diagnosed with lymphoma, leukemia, or myeloma in the United States in 2022 is 186,400.

Based on Region

North America to Dominate Global Sales Owing to Adoption of (Yescarta) Axicabtagene Ciloleucel Medicine

In 2022, the North American region emerged as the dominant player in the CAR T-Cell Therapy market. The increasing burden of chronic conditions such as cancer and autoimmune disorders, rise in research and development efforts, and strong and established market players. Furthermore, the increasing number of regulatory approvals in the United States and Canada, as well as the region's changing reimbursement structure, have hastened the penetration of these medicines, resulting in significant market growth. The United States' dominance in the global market has been attributed largely to the region's strong research, commercial basis, and huge number of clinical studies for CAR T-Cell Therapy being conducted across the country. This is due to a rise in the number of life sciences companies working in this region on CAR T-cell research and commercialization, as well as advances in quality control systems.

The CAR T-Cell Therapy industry in Asia Pacific is rapidly growing in popularity. The large pool of patients seeking cancer treatment, the increasing prevalence of cancer, investments by the market's major players, growing government spending on healthcare, and increasing disposable income of the population all contribute to improved access to cancer treatment are driving the market's growth.

Competitive Landscape

The global CAR T-Cell Therapy market is highly competitive, with various key players operating in the industry. Some of the major companies in the market include Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), and Caribou Biosciences Inc. (U.S.) to name a few. These businesses are concentrating their efforts on R&D in order to create unique and long-lasting products. Furthermore, strategic alliances, mergers, and acquisitions are common in the market as businesses seek to extend their product offerings and market presence.

The key players in the global CAR T-Cell Therapy market include - Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium) among others.

Recent Market Developments

  • In December 2022, - CARsgen Therapeutics Co., Ltd. and Shanghai Cancer Institute partnered to develop a new technology that can significantly improve T cells' antitumor capabilities. The CARsgen and Shanghai Cancer Institute research teams created CAR T-Cell Therapy that overexpressed Runx3 and discovered that Run-CAR T-Cell Therapy had longer anticancer activity and better tumor control than standard chimeric antigen receptor T-cell therapy.
  • In November 2022, relapsed or refractory large B cell lymphoma (LBCL) and relapsed or refractory B cell non-Hodgkin lymphoma (BCL) were given the FDA's designations for Regenerative Medicine Advanced Therapy (RMAT) and fast track, respectively, according to Caribou Biosciences, Inc.
  • In June 2022, The University of Ottawa demonstrated positive results for one of the first Canadian-developed CAR T-Cell Therapys for cancer in a clinical trial known as Canadian-Led Immunotherapies in Cancer-01 (CLIC-01). This therapy's manufacturing technique is unique, which opens the door to more inexpensive and equitable treatment choices.

Segmentation of the Global CAR T-Cell Therapy Market

Parameter Details
Segments Covered

By Drug Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Other Drug Types

By Indication

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Other Indications

By End User

  • Hospitals
  • Cancer Treatment Centers

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • Celgene Corporation (U.S.)
  • Cartesian Therapeutics Inc. (U.S.)
  • Miltenyi Biotech (Germany)
  • Autolus Therapeutics (UK)
  • Caribou Biosciences Inc. (U.S.)
  • Gilead Sciences Inc. (U.S.)
  • Merck & Co. Inc. (U.S.)
  • Intellia Therapeutics (U.S.)
  • Juno Therapeutics Inc. (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Novartis AG (Switzerland)
  • Bluebird Bio Inc. (U.S.)
  • Sorrento Therapeutics Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Cellectis (France)
  • Celyad Oncology (Belgium)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
Pricing and purchase options Avail of customized purchase options to meet your exact research needs. Explore purchase options

FAQ
Frequently Asked Question
  • The global CAR T-Cell Therapy valued at USD 2 Billion in 2022 and is expected to reach USD 5.9 Billion in 2030 growing at a CAGR of 14.6%.

  • The prominent players in the market are Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis (France), Celyad Oncology (Belgium).

  • The market is project to grow at a CAGR of 14.6% between 2023 and 2030.

  • The driving factors of the CAR T-Cell Therapy include

    • Surge in prevalence of cancer

  • North America was the leading regional segment of the CAR T-Cell Therapy in 2022.